TTVR System
Severe Tricuspid Regurgitation (TR)
Investigational / Pre-clinicalActive
Key Facts
Indication
Severe Tricuspid Regurgitation (TR)
Phase
Investigational / Pre-clinical
Status
Active
Company
About Laplace Interventional
Laplace Interventional is an early-stage, pre-revenue medical device company focused on the significant unmet need in tricuspid regurgitation (TR). The company is developing a proprietary transcatheter valve replacement (TTVR) system designed for percutaneous delivery, which could offer a safer, less invasive alternative to high-risk surgery. Operating from Plymouth, MN, and founded in 2018, the company is in the pre-clinical or early clinical investigation stage. Its success hinges on demonstrating the safety and efficacy of its novel device in a complex anatomical and competitive landscape.
View full company profileTherapeutic Areas
Other Severe Tricuspid Regurgitation (TR) Drugs
| Drug | Company | Phase |
|---|---|---|
| Topaz TTVR System | TRiCares | Pivotal |